# RETEVMO

NDC: 0002-5340
Generic name: selpercatinib
Labeler / Manufacturer: Eli Lilly and Company
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: TABLET, COATED
Routes: ORAL
Marketing started: 20240410

FDA application: NDA218160

## Active ingredients

- SELPERCATINIB: 40 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0002-5340"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0002-5340
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828